top of page

Unlocking new Aptamer therapeutics with Generative AI

Learn more about PentaBind

Targeting of Any Protein

We design therapeutic drugs to target previously 'Undruggable' human proteins; the largest class of human proteins and a driver of multiple cancers and diseases


Our proprietary AI-based platform applies a powerful Generative AI approach to rapidly design aptamers (short, single-stranded RNA or DNA sequences) that have a higher performance when compared to aptamers developed in physical laboratory experiments such as SELEX.

Leveraging recent breakthroughs in mRNA vaccine development and antisense drugs, we design oligo drugs with a novel moeity: protein binding


A Platform TechBio Company

PentaBind is a platform TechBio company consisting of bioinformaticians, data scientists, biophysicists, engineers and synthetic biology experts, who's CEO is a serial entrepreneur (1x biotech exit). They are backed by the prolific venture capital firm, Entrepreneur First and supported by Panacea Stars and P4SY.



Generative Algorithms and Aptamers will unlock the next generation of therapeutics


Contact us for partnership or investment enquiries, and job opportunities

  • LinkedIn
London City

Subscribe To Our Mailing List

Thanks for submitting!

bottom of page